Prices of key anti-diabetic drug empagliflozin crashed by as much as 90 per cent to ₹5.5 per tablet as several pharma ...

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic ...

Alivus Life Sciences Ltd share price was up by 0.64% from the previous closing price of ₹1,017.45. Who are peers of Alivus Life Sciences Ltd? The peers of Alivus Life Sciences Ltd are Sun ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...

Glenmark and Alkem Labs launched the generic version as well as its Fixed Dose Combination (FDCs) of Empagliflozin in India.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

HDFC Mid-Cap Opportunities Fund (G) 1115.56 87,22,482 1.65 HDFC Mid-Cap Opportunities Fund (IDCW) 1115.56 87,22,482 1.65 HDFC Mid-Cap Opportunities Fund - Direct ...

India's equity benchmark indices Sensex and Nifty were flat on Wednesday, as gains in Reliance Industries and Bharti Airtel, ...

Get all latest & breaking news on Jp Power. Watch videos, top stories and articles on Jp Power at moneycontrol.com.

Glenmark Pharmaceuticals Ltd. on Wednesday announced that it has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa ...

Glenmark Pharmaceuticals announced today the launch of Empagliflozin and its fixed-drug combinations in India under the brand names Glempa, Glempa-L, and Glempa-M. The shares of Glenmark ...

However, 61% of respondents said they would prefer that prices of goods and services go down instead of their income increasing (39%). That share has decreased slightly since 2023, Morning Consult ...